Myovant Sciences Ltd.

Sumitomo Pharma Co., Ltd. has decided to cut another 400 employees at its US subsidiary Sumitomo Pharma America, Inc. (SPMA) after already reducing headcount there by 500 in an earlier reorganization

Following a recent Woman in Advanced Therapies event, part of Phacilitate’s 2023 Advanced Therapies Europe conference, In Vivo spoke with organizers, attendees and industry leaders about opportuniti

Royalty financings were relatively few and far between in the first quarter of 2022, but the number of these financings more than doubled in Q1 of 2023 – from three to seven – and the amount of money

ImmunoGen, Inc. and Protagonist Therapeutics, Inc. accomplished in early April what has become increasingly difficult for public biotechnology companies to do when they accessed significant amounts